Expression of bone morphogenetic protein 6 in non‑small cell lung cancer and its significance

Xiong,Wei; Wang,Li; Yu,Fenglei

doi:10.3892/ol.2018.9781

Expression of bone morphogenetic protein 6 in non‑small cell lung cancer and its significance

Authors:
- Wei Xiong
- Li Wang
- Fenglei Yu
View Affiliations

Affiliations: Department of Thoracic Surgery, First Affiliated Hospital, Xiamen University, Xiamen, Fujian 361003, P.R. China, Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: November 30, 2018 https://doi.org/10.3892/ol.2018.9781
Pages: 1946-1952

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the expression and clinical significance of bone morphogenetic protein 6 (BMP‑6) in patients with non‑small cell lung cancer (NSCLC). The tumor and adjacent normal lung tissues were harvested from 65 patients with NSCLC. BMP‑6 mRNA expression was measured by reverse transcription‑quantitative polymerase chain reaction, while protein expression was measured using immunohistochemistry or an ELISA. Cell viability was determined using Cell Counting Kit‑8. The association of BMP‑6 mRNA expression with the prognosis of patients with NSCLC was analyzed using the Kaplan‑Meier plotter database. BMP‑6 mRNA expression in NSCLC tumor tissues was significantly reduced, compared with the adjacent normal lung tissues (P<0.001), yet no significant differences were observed between patients with different clinicopathological features (P>0.05). The expression level of BMP‑6 protein in NSCLC tumor tissues was significantly reduced, compared with the adjacent normal lung tissues (P<0.05). Analysis with the Kaplan‑Meier plotter database revealed that patients with NSCLC with low BMP‑6 mRNA expression had a reduced overall survival rate (P<0.01). The active BMP6 protein significantly inhibited cell proliferation in H460, H1299, A549 and H520 cells. In conclusion, BMP‑6 is a tumor suppressor in lung cancer and loss of BMP‑6 expression is significantly associated with a poor prognosis in patients with NSCLC.

View Figures

View References

1	Hoffman RM and Sanchez R: Lung cancer screening. Med Clin North Am. 101:769–785. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
3	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7(pii): 1700702017. View Article : Google Scholar : PubMed/NCBI
4	Clement JH, Sänger J and Höffken K: Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer. 80:250–256. 1999. View Article : Google Scholar : PubMed/NCBI
5	Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A and Borset M: Bone morphogenetic protein-5, −6 and −7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 23:3024–3032. 2004. View Article : Google Scholar : PubMed/NCBI
6	Chheang S and Brown K: Lung cancer staging: Clinical and radiologic perspectives. Semin Intervent Radiol. 30:99–113. 2013. View Article : Google Scholar : PubMed/NCBI
7	Chen Q, Wang L, Ma Y, Wu X, Jin L and Yu F: Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer. 5:14–24. 2014. View Article : Google Scholar : PubMed/NCBI
8	Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, et al: Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 4:736–754. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kraunz KS, Nelson HH, Liu M, Wiencke JK and Kelsey KT: Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. British J Cancer. 93:949–952. 2005. View Article : Google Scholar
10	Vukicevic S and Grgurevic L: BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev. 20:441–448. 2009. View Article : Google Scholar : PubMed/NCBI
11	Otani H, Otsuka F, Inagaki K, Suzuki J and Makino H: Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells. Acta Med Okayama. 64:213–218. 2010.PubMed/NCBI
12	Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS and Pratap J: Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer. 11:272012. View Article : Google Scholar : PubMed/NCBI
13	Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, et al: Bone morphogenic protein 6: A member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 28:3866–3879. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wach S, Schirmacher P, Protschka M and Blessing M: Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene. 20:7761–7769. 2001. View Article : Google Scholar : PubMed/NCBI
15	Takahashi M, Otsuka F, Miyoshi T, Otani H, Goto J, Yamashita M, Ogura T, Makino H and Doihara H: Bone morphogenetic protein 6 (BMP-6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol. 199:445–455. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA and Kim SJ: Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res. 9:6046–6051. 2003.PubMed/NCBI
17	Johnsen IK, Kappler R, Auernhammer CJ and Beuschlein F: Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res. 69:5784–5792. 2009. View Article : Google Scholar : PubMed/NCBI
18	Kraunz KS, Nelson HH, Liu M, Wiencke JK and Kelsey KT: Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signaling pathways in lung cancer. Br J Cancer. 93:949–952. 2005. View Article : Google Scholar : PubMed/NCBI
19	Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W and Zhong XY: Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene. 28:2969–2978. 2009. View Article : Google Scholar : PubMed/NCBI
20	Daibata M, Nemoto Y, Bandobashi K, Kotani N, Kuroda M, Tsuchiya M, Okuda H, Takakuwa T, Imai S, Shuin T and Taguchi H: Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. Clin Cancer Res. 13:3528–3535. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, Otani H, Kubo T, Aoe K, Fujimoto N, et al: The aberrant promoter methylation of BMP3b and BMP-6 in malignant pleural mesotheliomas. Oncol Rep. 20:1265–1268. 2008.PubMed/NCBI
22	Taniguchi A, Nemoto Y, Yokoyama A, Kotani N, Imai S, Shuin T and Daibata M: Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. Int J Cancer. 123:1824–1831. 2008. View Article : Google Scholar : PubMed/NCBI
23	Yang S, Zhong C, Frenkel B, Reddi AH and Roy-Burman P: Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 65:5769–5777. 2005. View Article : Google Scholar : PubMed/NCBI
24	Esteller M: Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 16 Spec No. 1:R50–R59. 2007. View Article : Google Scholar
25	Li S, Sheng B, Zhao M, Shen Q, Zhu H and Zhu X: The prognostic values of signal transducers activators of transcription family in ovarian cancer. Biosci Rep. 37(pii): BSR201706502017. View Article : Google Scholar : PubMed/NCBI
26	Ma YM and Zhao S: Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer. Onco Targets Ther. 9:1981–1988. 2016. View Article : Google Scholar : PubMed/NCBI